3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
Cyclophosphamide
23
venetoclax
17
Dexamethasone
16
pembrolizumab
15
fludarabine
15
Cytarabine
13
pomalidomide
8
Rituximab
8
Gemcitabine
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
selinexor
6
Paclitaxel
6
Injections
6
Immunotherapy, Adoptive
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Oxaliplatin
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
ficlatuzumab
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled